Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors

Abstract

People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic review and random‐effects meta‐analysis of prospective and retrospective, nationwide and targeted cohort studies assessing mortality risk in people with schizophrenia versus the general population or groups matched for physical comorbidities or groups with different psychiatric disorders, also assessing moderators. Primary outcome was all‐cause mortality risk ratio (RR); key secondary outcomes were mortality due to suicide and natural causes. Other secondary outcomes included any other specific‐cause mortality. Publication bias, subgroup and meta‐regression analyses, and quality assessment (Newcastle‐Ottawa Scale) were conducted. Across 135 studies spanning from 1957 to 2021 (schizophrenia: N=4,536,447; general population controls: N=1,115,600,059; other psychiatric illness controls: N=3,827,955), all‐cause mortality was increased in people with schizophrenia versus any non‐schizophrenia control group (RR=2.52, 95% CI: 2.38‐2.68, n=79), with the largest risk in first‐episode (RR=7.43, 95% CI: 4.02‐13.75, n=2) and incident (i.e., earlier‐phase) schizophrenia (RR=3.52, 95% CI: 3.09‐4.00, n=7) versus the general population. Specific‐cause mortality was highest for suicide or injury‐poisoning or undetermined non‐natural cause (RR=9.76‐8.42), followed by pneumonia among natural causes (RR=7.00, 95% CI: 6.79‐7.23), decreasing through infectious or endocrine or respiratory or urogenital or diabetes causes (RR=3 to 4), to alcohol or gastrointestinal or renal or nervous system or cardio‐cerebrovascular or all natural causes (RR=2 to 3), and liver or cerebrovascular, or breast or colon or pancreas or any cancer causes (RR=1.33 to 1.96). All‐cause mortality increased slightly but significantly with median study year (beta=0.0009, 95% CI: 0.001‐0.02, p=0.02). Individuals with schizophrenia <40 years of age had increased all‐cause and suicide‐related mortality compared to those ≥40 years old, and a higher percentage of females increased suicide‐related mortality risk in incident schizophrenia samples. All‐cause mortality was higher in incident than prevalent schizophrenia (RR=3.52 vs. 2.86, p=0.009). Comorbid substance use disorder increased all‐cause mortality (RR=1.62, 95% CI: 1.47‐1.80, n=3). Antipsychotics were protective against all‐cause mortality versus no antipsychotic use (RR=0.71, 95% CI: 0.59‐0.84, n=11), with largest effects for second‐generation long‐acting injectable anti­psychotics (SGA‐LAIs) (RR=0.39, 95% CI: 0.27‐0.56, n=3), clozapine (RR=0.43, 95% CI: 0.34‐0.55, n=3), any LAI (RR=0.47, 95% CI: 0.39‐0.58, n=2), and any SGA (RR=0.53, 95% CI: 0.44‐0.63, n=4). Antipsychotics were also protective against natural cause‐related mortality, yet first‐generation antipsychotics (FGAs) were associated with increased mortality due to suicide and natural cause in incident schizophrenia. Higher study quality and number of variables used to adjust ...

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey

“…[3][4][5] Despite the relatively low prevalence, schizophrenia is associated with substantial health, societal, and economic burden, including high healthcare resource utilization [6][7][8] and increased risk of premature mortality, disability, mental health comorbidities, and suicide. [9][10][11][12][13][14][15] Furthermore, the difficult symptoms associated with schizophrenia profoundly decrease patients' quality of life and daily functioning. 16,17 As a result of confirmed cases of illness caused by a SARS-CoV-2 Novel Coronavirus (2019-nCoV or COVID- 19), the US Secretary of Health and Human Services determined the existence of a public health emergency on January 27, 2020.…”

Association between Short-Term Exposure to Ozone and Heart Rate Variability: A Systematic Review and Meta-Analysis

“…There are eight items in the NOS, and the items are categorized into three dimensions, including selection, comparability, and outcomes. Studies were evaluated based on an NOS score from 0 to 9, with a score greater than 7 indicating high quality, a score between 5 and 6 indicating moderate quality, and one less than 5 indicating low quality [ 17 ].…”

Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects

“…The concomitant comorbidity with other mental disorders determines the higher rates in symptomatology relapse, hospitalizations, suicidality, and family and social issues (such as higher rates of incarceration due to mental disorder relapse, treatment discontinuation, higher impulsivity and violent behaviors, and so forth), as well as a higher risk of negative outcomes in the short-term, including higher mortality rates [ 15 , 16 ]. A very recent meta-analysis showed that all causes of mortality were increased in people with schizophrenia, compared to the control group [ 17 ]. The specific causes of mortality included suicide, injury, poisoning, pulmonary diseases, endocrine diseases, respiratory diseases, urogenital diseases, diabetes, cancer, and cardio-cerebrovascular causes [ 17 ].…”

“…A very recent meta-analysis showed that all causes of mortality were increased in people with schizophrenia, compared to the control group [ 17 ]. The specific causes of mortality included suicide, injury, poisoning, pulmonary diseases, endocrine diseases, respiratory diseases, urogenital diseases, diabetes, cancer, and cardio-cerebrovascular causes [ 17 ]. Moreover, it has also been found that treatment with an antipsychotic (AP) drug, in particular with second-generation long-acting injectable antipsychotics (SGA-LAIs), seems to be protective against all causes of mortality [ 17 ].…”